Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
NCT ID: NCT01084330
Last Updated: 2020-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
68 participants
INTERVENTIONAL
2010-04-30
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AUY922
AUY922
70mg/m2
Docetaxel or Irinotecan
Docetaxel
Docetaxel 75mg/m2
Irinotecan
Iriniotecan 350mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AUY922
70mg/m2
Docetaxel
Docetaxel 75mg/m2
Irinotecan
Iriniotecan 350mg/m2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One previous line of chemotherapy
* Progressive disease
* One measurable lesion
* Blood tests within protocol ranges
* (WHO) Performance Status ≤ 1
* Able to sign informed consent
Exclusion Criteria
* No coumarin type anticoagulants
* No liver or kidney disease
* No impaired heart function
* No pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC/Kenneth Norris Comprehensive Cancer Center USC/Norris
Los Angeles, California, United States
University of California at Los Angeles Dept. of UCLA (4)
Los Angeles, California, United States
Horizon Oncology Center
Lafayette, Indiana, United States
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU
Baltimore, Maryland, United States
Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)
Lake Success, New York, United States
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology
Dallas, Texas, United States
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
Tyler, Texas, United States
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Toulouse, , France
Novartis Investigative Site
Erlangen, , Germany
Novartis Investigative Site
Ulm, , Germany
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Pisa, PI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Napoli, , Italy
Novartis Investigative Site
Utrecht, , Netherlands
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Singapore, , Singapore
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Bellinzona, , Switzerland
Novartis Investigative Site
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan
Novartis Investigative Site
Tainan City, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Surrey, England, United Kingdom
Novartis Investigative Site
Sutton, Surrey, United Kingdom
Novartis Investigative Site
Glasgow, , United Kingdom
Novartis Investigative Site
Leicester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CAUY922A2202 can be found on the Novartis Clinical Trial Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-015407-47
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CAUY922A2202
Identifier Type: -
Identifier Source: org_study_id